Patients
In PRIME, 200 patients were screened and 151 were randomized (75 dupilumab and 76 placebo) at 58 study sites in eight countries/regions. In PRIME2, 221 patients were screened and 160 were randomized (78 dupilumab and 82 placebo) at 55 study sites in 11 countries/regions (Fig. 